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aims of our analysis were to describe clinical presentation, response to current medical treatments, and
to evaluate the response of refractory EGE to anti-integrin therapy. METHODS Patients with confirmed
diagnosis of EGE fulfilling the diagnostic criteria: (1) the presence of gastrointestinal symptoms, (2) dense
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release steroids in 21/22 (95%) patients, proton pump inhibitors in 7/22 (32%), TNF฀ inhibitors in
3/22 (14%), and vedolizumab in 4/22 (18%) patients. In 3/4 of steroid-refractory patients vedolizumab
induced a clinical and histological improvement. CONCLUSIONS The combination of highly variable
clinical presentation, subtle endoscopic abnormalities, and involvement of several GI segments undermines
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in the majority of patients to induce remission. Response to the integrin blocker vedolizumab suggests
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Eosinophilic gastroenteritis (EGE) is a rare, chronic-inflammatory condition of the 
gastrointestinal tract. Little is known about its natural history and treatment outcomes. The 
aims of our analysis were to describe clinical presentation, response to current medical 
treatments and to evaluate the response of refractory EGE to anti-integrin therapy.  
Methods  
Patients with confirmed diagnosis of EGE fulfilling the diagnostic criteria: 1) presence of 
gastrointestinal symptoms, 2) dense eosinophilic infiltration of the gastrointestinal mucosa and 
3) exclusion of other conditions leading to gastrointestinal eosinophilia were included in this 
analysis. In patients non-responding to corticosteroids and/or anti-TNF treatment the integrin 
blocker vedolizumab was used. 
Results 
EGE patients (n=22) were predominantly female (63%) with a median age at diagnosis of 41.5 
years. The most frequent symptoms were abdominal pain (100%), diarrhea (59%), 
nausea/vomiting (36%) and bloating (27%). No pathognomonic endoscopic alterations were 
found. Eosinophilic infiltration was observed in the majority of patients in more than one 
segment. Patients were treated with systemic steroids, topical and enteral release steroids in 
21/22 (95%) patients, proton-pump inhibitors in 7/22 (32%), TNFα inhibitors in 3/22 (14%) and 
vedolizumab in 4/22 (18%) patients. In 3/4 of steroid-refractory patients vedolizumab induced 
a clinical and histological improvement.  
Conclusions  
The combination of highly variable clinical presentation, subtle endoscopic abnormalities and 
involvement of several GI segments undermines the difficulty to diagnose EGE and the need 
for structured biopsy sampling. Corticosteroids were efficient in the majority of patients to 




induce remission. Response to the integrin-blocker vedolizumab suggests further assessment 
in refractory cases.  
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Eosinophilic gastroenteritis (EGE) was described 80 years ago by the surgeon Kaijser and 
represents a chronic, immune-mediated inflammatory disorder with an eosinophil-predominant 
infiltration of the intestinal wall [1-3]. EGE is a rare, heterogeneous and poorly defined clinical 
condition, which can involve any segment of the gastrointestinal (GI) tract. So far, 
epidemiologic studies indicate a low prevalence rate of below 5 patients per 100`000 
inhabitants. EGE can affect both children and adults [4, 5]. The clinical presentation with 
unspecific symptoms may mimic other gastrointestinal diseases, in particular irritable bowel 
syndrome. As a consequence of the diagnostic challenge, EGE is likely underdiagnosed and 
the prevalence might be markedly higher. The diagnosis is based on the following criteria: 
presence of gastrointestinal symptoms, eosinophilic infiltration of one or more segments of the 
gastro-intestinal tract and exclusion of other causes of intestinal eosinophilia, in particular drug 
reactions, food allergies, celiac disease, parasitic infections, hypereosinophilic syndromes and 
inflammatory bowel disease [6]. These conditions should be ruled out before the diagnosis of 
EGE can be established. So far, no consensus has been reached regarding the histological 
criteria for diagnosing EGE in general and a threshold defining a pathological count of 
eosinophils in specific, as the mucosa of the GI tract, with the exception of the esophagus, 
harbors eosinophils even under physiological conditions [7-9]. EGE remains therefore a 
diagnostic challenge for the clinician and for the pathologist. So far, two classifications have 
been used to classify the disease: The first, the Klein-classification is based on the depth of 
the eosinophilic infiltration on surgical specimens. It describes three different forms: mucosal 
disease, muscle layer disease and subserosal disease [1]. The second classification is based 
on the longitudinal pattern of involvement [4, 5]. The treatment of EGE is another challenge, 
as recommendations are currently exclusively based on case reports/case series as no 
controlled trials are available. Our study has the following four purposes: first to provide a 
comprehensive description of the clinical and endoscopical features of a respectable cohort of 




EGE patients, second to describe the natural course of the disease over time, third to evaluate 
the response to the current medical treatments and finally to report the experience of treatment 
with the gut selective α4β7 integrin-blocker vedolizumab. 
  






We performed a retrospective cohort analysis of patients of the Swiss EoE Clinics, a tertiary 
referral center for eosinophilic gastro-intestinal diseases (EGIDS). Patients of any age with 
EGE were identified from the Swiss EoE Database (SEED) and clinical presentation, 
endoscopic and histological features as well as therapeutic decisions were taken from the 
patient records. Symptoms, endoscopic and histological alterations were documented 
prospectively. All patients had previously given their informed consent for inclusion into the 
(SEED). The study was approved by the local ethic committee (EKNZ 2015-388). In addition, 
a small series of patients with EGE refractory to, or dependent on, corticosteroids were treated 
with the α4β7 integrin antibody vedolizumab (Entyvio), on a compassionate use basis, after 
signing an informed consent. 
 
Patients and Definitions  
The SEED is a nationwide database with voluntary referral, into which patients with 
Eosinophilic Gastro-Intestinal Disorders (EGIDS) have been prospectively included since 
1989. Currently, the database contains data on 1153 EGIDS patients, of which 43 were initially 
classified as EGE, and 1110 as Eosinophilic Esophagitis (EoE) (Figure 1). In 1991 and 1995 
the first two patients with EGE were included. Inclusion of further EGE patients was between 
2003 and november 2017.  According to the literature, patients were classified as EGE when 
the following criteria were fulfilled: 1) presence of gastrointestinal symptoms, 2) dense 
eosinophilic infiltration in biopsies taken from the gastrointestinal tract and/or high eosinophil 
numbers in ascites, 3) absence of infectious/parasitic or extra-intestinal diseases. Inclusion 
criteria for this analysis were confirmed diagnosis of EGE, treatment performed at the Swiss 
EoE Clinic and a complete documentation of the data. Patients with an incomplete dataset 




and patients with isolated eosinophilic infiltration of the esophagus were excluded from this 
analysis.  
 
Assessment of endoscopic and histological alterations 
Esophago-gastro-duodenoscopy (EGD) and/or ileo-colonoscopy were performed in all 
patients by a board-certified gastroenterologist (AS). Endoscopic alterations were assessed 
and biopsies obtained for histological evaluation. Histological analysis of biopsies was 
performed on 4μm paraffin sections of hematoxylin-eosin stained layered cuts (≥10). All levels 
were surveyed and the eosinophils in the most densely infiltrated area were counted in 5 
consecutive hpf (microscope Zeiss Axiophot, Plan-Neofluar 40, ocular magnification 10x, area 
of microscopic field 0.3072 mm2).  
 
Patients treated with vedolizumab 
Prior to the initiation of compassionate use of vedolizumab extensive counselling of the patient 
regarding the mechanism of action, therapeutic experiences in IBD as well as safety data was 
provided. All patients were informed that there is no evidence from clinical trials or case series 
on the potential role of this therapeutic principle in patients with EGE. In addition, the rationale 
for this therapeutic approach based on the molecular mechanisms of action of anti-integrin 
treatment was discussed. All patients provided oral and signed informed consent to treatment 
with vedolizumab. Dosing was performed according to standard practice used for treatment in 
patients with inflammatory bowel disease for induction and maintenance with 300 mg infusions 
at week 0, 2 and 6 followed by maintenance treatment every 8 weeks. At baseline, clinical 
symptoms were assessed and Patient Global Assessment (PGA) of overall clinical symptoms 
was determined by patient inquiry and set to 5 per definition at baseline on a scale from 0-10. 
During the treatment phase, assessment of the PGA was performed at each clinical visit with 
the following question: How would you personally judge your overall evolution of clinical 




symptoms during treatment on a scale from 0-10 if the starting point was set to 5/10. Peripheral 
blood eosinophil count (normal range: 350 Eos/mm3) and eosinophilic cationic protein (ECP) 
(normal range: <18 µg/l) were the main biochemical parameters of interest to determine 
biochemical response. Baseline and follow up endoscopies were performed according to the 
original disease localization. Severity grade of endoscopic alterations was assessed by the 
investigator on a visual analogue scale (VAS) from 0-10 (with 0 indicating no visual 
abnormalities and 10 most severe signs of active EGE). In cases where there were several 
segments with active disease, relative weighing with predominant consideration of the most 
affected segment was done by the main clinical investigator (AS). Quantitative eosinophilic 
count in eosinophils per high power field (eos/hpf) in the main involved GI-segment was used 
as histological outcome. Clinical, biochemical, endoscopic and histological responses were 
evaluated at the most recent follow-up in cases where there was ongoing treatment with 
vedolizumab, or at the time of treatment withdrawal. Follow up endoscopy was performed in 
all patients at the time of the 4th vedolizumab infusion (+/- 10 days), with the exception of 
patient 2 where endoscopy was performed prematurely at the time of the third infusion 
because of ongoing severe abdominal pain. 
 
Data collection and statistical analysis 
All data were anonymized. The following data were collected: patient characteristics, baseline 
disease characteristics, peak eosinophil counts, laboratory findings, stool analysis for 
parasites, treatment characteristics, disease course. 
Data extraction from source data was performed using MS Excel. Descriptive statistics 
included mean and standard deviation (SD) for metric variables and medians and range for 
ordinal variables and clinical parameters. 
  





Characteristics of EGE cohort  
In our database we identified 22 patients, 8 male and 14 female patients with eosinophilic 
gastroenteritis fulfilling the established diagnostic criteria as well as the inclusion criteria for 
this analysis (Figure 1). Patients had a median age of 41.5 years at diagnosis and the median 
interval between first symptoms and diagnosis was 2.5 year (Table 1). In 9/22 (41%) patients 
there was a clinical history of allergies. These patients had a history of atopic conditions 
including asthma, allergic rhinitis, atopic dermatitis and food allergy. Only two patients had a 
positive family history for eosinophilic gastrointestinal diseases (EGIDS). All patients with EGE 
presented with abdominal pain. Other frequent symptoms reported by these patients were 
diarrhea in 59% and/or nausea/vomiting in 36% (Table 1). Mostly, there were no relevant 
findings on physical examination, except in two patients with ascites. Laboratory tests revealed 
elevated peripheral eosinophilic count in 59% of patients. Four patients had a discrete anemia, 
including one patient with a deep ulceration in the duodenum presenting with melena and a 
hemoglobin drop to 111 g/l on one occasion. Serum level of total IgE was elevated in 8 of 13 
analyzed patients, C-reactive protein in 3 of 12, fecal calprotectine in 4 of 6 and in 8 of 9 
analyzed patients the eosinophilic cationic protein (ECP) was increased (median: 47.1 μg/l, 
range: 4.8 -107 μg/l). Stool examinations and cultures were negative for parasites and other 
common pathogens.  
Initial gastroscopy and ileo-colonoscopy was performed in 82% (18/22) and 82% (18/22) 
patients respectively. The majority of patients had no, or only subtle, endoscopic 
abnormalities. The most prominent signs were alterations of the esophageal mucosa in 7 out 
of 9 patients with histologically confirmed affection of the esophagus. In one patient 
erythematous alterations in the antrum were observed but with no evidence of eosinophilic 
infiltration on histological evaluation and two patients were found with duodenitis but with no 
increased eosinophilic infiltrates. In contrast, one patient with a persistent, deep duodenal 




ulceration had eosinophilic infiltration on repeat upper endoscopy. The most prominent finding 
in the evaluation of the lower gastrointestinal tract were signs of colitis with erythematous 
mucosal changes in 6/22 (23%) patients, sigmadiverticulosis in 4/22 (18%) patients, with 
erythematous changes in one patient with eosinophilic infiltration. Two patients had mucosal 
changes in the terminal ileum and ascending colon of small nodular aspect, which proved to 
be eosinophilic infiltrates on histological evaluation. However, in 11/22 (50%) patients a normal 
appearing mucosa was found. The histological evaluation showed that eosinophilic infiltration 
could occur in all segments of the gastrointestinal tract, but predominantly in the colon (68%) 
and the esophagus (41%) followed by the duodenum (32%) and terminal ileum (23%) (Table 
2). At diagnosis, counts ranged between 15 and 150 eos/hpf in the most highly involved 
locations and the observation of eosinophilic microabscesses, intraepithelial eosinophils and 
eosinophilic degranulation were considered as additional histological features. Involvement of 
multiple segments of the gastro-intestinal tract and/or organs was observed in 17 patients 
(77%). In our cohort 20 patients suffered from mucosal disease and only 2 patients had serosal 
affection, with both patients initially presenting with eosinophilic ascites. Longitudinal analysis 
of the clinical course in 20 patients with mucosal type revealed that 30% had a single flare, 
30% a recurring course with multiple flares and 40% suffered from a continuous disease 
course. Interestingly, more than 50% of patients with affection of the lower gastro-intestinal 
tract had a single flare course (Figure 2a). In contrast, when the upper gastro-intestinal tract 
was affected only 25% of patients had a single disease course whereas the other patients 
suffered from either a recurring or continuous disease course. All patients with affection of 
segments in both the lower and upper gastro-intestinal tract suffered from either a recurring or 
continuous disease course. An increasing number of involved segments was associated with 
a recurring or continuous disease course (Figure 2b). Two patients with pancreatic 
manifestation had intestinal involvement of the colon and one patient of two segments of the 
upper gastrointestinal tract (esophagus and duodenum). One patient with affection of both the 




lower and upper gastrointestinal tract (colon and stomach) had concomitantly diagnosis of an 
eosinophilic hepatitis and eosinophilic acalculous cholecystitis. These four patients with 
pancreatic or hepatitic/cholezystitic manifestation had either a recurring or continuous disease 
course. One patient with a continuous disease course showed primarily affection of the colon 
and 39 months later an unusual switch to esophageal involvement was observed. 
Treatment was based on severity of symptoms, on localization of affected segments in the 
gastro-intestinal tract and on clinical experience. Five patients were primarily sent to dietary 
counselling and dietary restrictions were implemented. In these patients an empirical 
elimination diet was initiated in a step up process starting with wheat elimination or cow milk 
elimination and progressing up to a dietary restriction typical for a six-food elimination diet (6-
FED). However, we did not observe clear improvement of symptoms. In 7/22 patients (32%) 
a proton pump inhibitor treatment was initiated, 3/22 (14%) were treated with antihistamines 
and 2/22 (9%) with a mast cell stabilizer with only mild or no clear evidence of clinical 
improvement (Table 3). All patients initially on PPI or antihistamine treatment were later 
switched to corticosteroids, except for one patient with a single flare self-limiting disease 
course. In total, 21/22 (95%) patients received at least one cycle of corticosteroid treatment. 
After the start of steroid treatment a tapering scheme was applied according to clinical 
assessment to reduce the corticosteroid dose to control for clinical symptoms. 8/21 (38%) of 
the patients were treated with topical steroids such as fluticasone (induction scheme for 2 
weeks 1mg twice daily and thereafter maintenance therapy of 250 μg twice daily) and 10/21 
(48 %) of the patients were treated with enteral release steroids such as budesonide (starting 
dose of 9 mg which was subsequently tapered according to clinical symptoms) . In 13/21 (62%) 
patients prednisone (0.75-1 mg/kg body weight) was used. Due to persistent clinical symptoms 
8/21 (38%) patients required continuous, long-term prednisone to maintain remission (5-10 
mg/day). In 4 patients refractory or dependent to steroids, biological therapy was initiated. In 




3/21 (14%) patients primarily TNFα inhibitors were started. Two of the 3 patients with a TNFα 
inhibitor therapy were treated with multiple TNFα inhibitors with only mild clinical response.  
 
Outcome of vedolizumab treatment in treatment-refractory EGE  
In 4 patients with treatment-refractory or steroid-dependent course (including three patients 
not responsive to TNFα treatment), α4β7 integrin antibody vedolizumab treatement was 
initiated. Patient and physician reported outcomes for the four patients with EGE treated with 
vedolizumab are shown in Figure 4.  
 
Patient 1: 24-year-old man with severe eosinophilic duodenitis 
A 24-year old man with eosinophilic gastroenteritis, diagnosed in 2009 with involvement of the 
esophagus and duodenum, suffered from chronic upper epigastric pain and dysphagia. The 
patient’s symptoms and a large deep duodenal bulb ulceration were refractory to systemic 
steroids, budesonide and subsequent anti-TNFα (adalimumab) treatment (Figure 3A). 
Induction and subsequent maintenance treatment with vedolizumab led to a complete 
resolution of dysphagia as well as eosinophilic infiltration in the duodenum, whereas epigastric 
pain did not completely disappear. An endoscopic evaluation after continuous treatment over 
12 months revealed a superficial duodenal bulb ulceration (Figure 3B). According to this 
overall favorable course of disease in the absence of systemic steroids, vedolizumab 
maintenance treatment is continued for cumulative 21 months.  
 
Patient 2: 28-year-old female with serosal small intestinal involvement 
A 28-year old female patient with severe systemic eosinophilia and ascites, diagnosed with 
EGE after laparoscopic full-thickness biopsy in 2012, predominantly suffered from non-bloody 
diarrhea, fatigue, weight loss and abdominal cramps with recurrent relapses during several 
courses of steroid tapering. After unsuccessful treatment with budesonide, thiopurines and two 




anti-TNFα agents (infliximab and adalimumab) vedolizumab was initiated. Due to failure of 
symptom control anti-integrin treatment was stopped after the induction phase in the 6th week.  
 
 
Patient 3: 56-year-old female with eosinophilic colitis 
A 56-year old female patient with chronic abdominal pain as the main clinical complaint was 
diagnosed with eosinophilic colitis with endoscopically unremarkable appearing mucosa with 
areas of edema and low vascular pattern (Figure 3C and D). She developed a steroid-
dependent disease course with increasing diarrhea. Intolerance to azathioprine and 6-
mercaptopurine, secondary loss of response to infliximab and certolizumab and finally a 
primary non-response to adalimumab were observed. Treatment with vedolizumab led to a 
decrease in non-bloody and painless diarrhea. However, due to relapsing symptoms 4-5 
weeks after the vedolizumab infusion, the infusion interval was shortened to 4 weeks with 
cumulative use of vedolizumab for 35 months. Clinical and histological improvement has been 
observed up to the present. 
 
Patient 4: 25-year-old female with eosinophilic gastroenteritis 
A 25-year old female patient with early onset of IBS-like abdominal symptoms including 
abdominal pain and irregular bowel movements presented with new onset dysphagia for a 
gastroenterological evaluation. A thorough endoscopic examination revealed typical features 
of EoE (Figure 3E) and nodular infiltrates of the terminal ileum (Figure 3F) and the entire colon. 
Due to refractory symptoms to budesonide a treatment with vedolizumab was initiated. By the 
end of week 14 improvements in diarrhea and abdominal pain but not dysphagia were 
observed. Maintenance treatment with vedolizumab is continuing with cumulative use of 
vedolizumab for 23 months. 





Eosinophilic gastroenteritis (EGE) is a rare but likely underdiagnosed inflammatory 
disease of the gastrointestinal tract. Due to the unspecific clinical presentation and the lack of 
clearly defined histologic criteria EGE is a diagnostic challenge for clinicians as well as for 
pathologists. We herein report on our clinical experience and therapeutic observations in 
patients with EGE as well as compassionate use of vedolizumab in four patients with treatment 
refractory disease course.  
The most comprehensive information about the natural course was provided in a French 
cohort analysis of 43 adult patients which identified three different patterns with single flare, a 
recurring and continuous disease course of EGE [22]. In our cohort patients with extensive 
disease and patients with affection of both the lower and upper gastrointestinal tract exhibited 
a recurring or continuous disease course more often. In contrast, patients with only affection 
of the lower gastrointestinal tract had a more favorable outcome. Of note, we observed a 
switch of the involved segments during the disease course in one patient. 
Our laboratory results revealed peripheral eosinophilia in 52% of the patients, a finding 
also observed by other authors [20-22]. Therefore, absence of peripheral eosinophilia is not 
sufficient to rule out EGE when it is clinically suspected and it is not reliable as an observational 
parameter to estimate disease activity, as patients may continue to have elevated eosinophil 
counts regardless of their histological response to therapy. However, high blood eosinophil 
counts at diagnosis were previously shown to be significantly associated with a high risk of 
clinical relapse [22]. Eosinophil degranulation and mediator release by activated eosinophils 
has been shown in tissue samples from patients with eosinophilic gastroenteritis [23-25]. In 
our cohort we found elevated serum eosinophilic cationic protein (ECP) in a portion of our 
patients. However, we did not see any difference in the outcome of the course of disease in 
these patients.  This limited observation does not suggest so far that ECP can be of use for 
diagnosis and monitoring of EGE.  




Endoscopic evaluation was unremarkable in about half of our patients as was similarly 
observed by other authors [5]. The most frequent endoscopic finding in our patient cohort was 
colitis and in the esophagus EoE-like alterations, while the most common gastric and duodenal 
finding described by other authors is mucosal erythema [5, 26]. Other unspecific signs can 
include mucosal hyperemia, thickening of folds, friability, areas of roughening, whitish specks, 
erosions, superficial ulcers, or nodularity [26]. Astonishingly, in many cases we found 
eosinophilic infiltration in biopsies from areas of normal endoscopic appearance. This apparent 
inconsistency may arise from the patchy nature of eosinophilic infiltration and from an 
infiltration restricted to the subepithelial layers, not visible on endoscopic evaluation. In these 
circumstances if suspicion of EGE is high, a full-thickness surgical biopsy should be 
performed. Capsule endoscopy could be an alternative option to search for intestinal 
abnormalities in the small intestine but the benefits of this approach must outweigh the 
drawbacks, in particular the impossibility of taking biopsies and the risk of impaction in case 
of strictures [27, 28]. To summarize, endoscopy might identify inflamed segments of the 
intestinal tract, but an unremarkable endoscopy does not exclude an eosinophilic 
inflammation. We therefore strongly recommend performing a structured biopsy sampling in 
patients with clinical suspicion of EGE, independent of the endoscopic appearance of the 
mucosa.  
So far, there is no established consensus on a diagnostic threshold with regard to 
eosinophil count for EGE for the various segments of the gastro-intestinal tract. For the 
stomach and duodenum in asymptomatic adults, a mean eosinophil count of generally less 
than 10 eosinophils per hpf in biopsies from different areas is considered normal [7, 8, 29]. In 
clinic practice, based on prior studies on healthy controls, peak eosinophil counts higher than 
30 eos/hpf in the stomach, 50 eos/hpf in the duodenum, and 30 eos/hpf in the large bowel 
(dependent on location) in an affected segment has been suggested when EGE is suspected 
[30]. In a review, Collins et al suggested less emphasis on eosinophil quantity and focusing 




more on additional pathologic changes. They also proposed using the term “mucosal 
eosinophilia” to describe increased numbers of mucosal eosinophils without other histologic 
alterations and reserving the term “EG/colitis” for cases with additional pathologic changes 
[31].  
Analysis of our treatment data revealed that corticosteroids were the mainstay of 
therapy in most of our EGE patients. Preferentially, prednisone and budesonide were used for 
gastro-intestinal as well as swallowed fluticasone for patients with esophageal involvement. 
To maintain remission, approximately a third of our patients required continuous, long-term 
prednisone. This observation is comparable with our recently published experience in a large 
cohort of patients with isolated EoE achieving deep remission (i.e. a composite of clinical, 
endoscopic and histological remission) on continuous treatment with topical steroids [32]. 
Besides immunosuppressive drugs such as azathioprine and 6-mercaptopurine, TNFα 
blockers are used for steroid-refractory or steroid-dependent disease course of chronic 
inflammatory conditions in the gut and also in several case series in patients with EGE [33-
35]. Since we observed only mild and frequently only transient clinical and biochemical 
response to treatment with both, azathioprine or TNFα blockers we performed a therapeutic 
trial with vedolizumab in 4 patients with refractory or steroid-dependent course of EGE. This 
monoclonal antibody acts against the α4β7 integrin heterodimer present on activated 
lymphocytes, blocks the interaction of this integrin with the mucosal addressin cell adhesion 
molecule (MAdCAM) 1, inhibits leukocyte binding to endothelial surface and prevents therefore 
extravasation of these cells into affected tissue. Vedolizumab has been shown to efficiently 
induce and maintain remission in Crohn’s disease and ulcerative colitis with moderate to 
severe disease course during an observation period of up to 152 weeks [36-40]. In addition to 
a very favorable side effect profile, the main rationale for choosing vedolizumab in this 
indication was the fact that the β7 subunit is also expressed on eosinophils and that MAdCAM-
1 (expressed on the endothelial cells of the GI-tract) seems to be upregulated upon 




inflammation [41]. In our case series clinical response, endoscopical as well as histological 
improvement was observed in two patients with affection of the lower gastrointestinal tract and 
one patient with eosinophilic duodenitis. Due to failure of symptom control, the anti-integrin 
treatment was stopped after the induction phase in one patient with serosal type of disease 
presenting with ascites. Partial response to treatment with vedolizumab with improved 
histology and reduction of steroids in two patients with a long disease course has been recently 
observed [42]. Thus, blocking the integrin-MAdCAM-1-interaction might be a novel therapeutic 
target in refractory cases of EGE. However, any conclusions on the efficacy of vedolizumab in 
EGE need to be drawn with great caution due to the small patient number reported in our case 
series and the unblinded, not fully standardized collection of efficacy data.  
There are several limitations due to the retrospective nature of our analysis of patients 
with EGE. Some patients referred for an expert opinion experienced a cross-sectional  
evaluation and therefore the cohort cannot be considered as a fully representative population 
of patients with EGE. This includes patients lacking clear signs of chronicity with an 
uncomplicated disease course where no obvious reasons for eosinophilic infiltration of the 
gastro-intestinal tract have been found and per definition are considered having EGE.  Also in 
our cohort only two patients suffered from the serosal type of EGE. As only these two patients 
received a full thickness biopsy, we cannot reliably provide information on the transmural 
affection in our patient cohort. This indicates that the serosal and muscular sub-type of EGE 
in our cohort may have been underdiagnosed. In addition, a referral of patients suffering from 
a complicated and treatment refractory disease course, may have led to a positive selection 
of difficult to treat patients and therefore the efficacy of some treatments cannot be 
conclusively assessed and may in fact even have been underestimated.  
 
Conclusion 




Our cohort of this rare and insufficiently understood gastrointestinal disease represents 
one of the largest observations. EGE is a patchy disease with variable eosinophilic infiltration 
of all layers of the GI tract. This suggests that diagnosis of EGE should be suspected in 
patients with long lasting unexplained chronic gastrointestinal symptoms and a standardized 
thorough endoscopic as well as histological evaluation of normal appearing intestinal 
segments should be performed  
Treatment with corticosteroids is central in the treatment of patients with EGE. Although 
vedolizumab induced clinical response in some patients with treatment refractory disease 
course of EGE, the efficacy of this drug needs to be evaluated for this indication with a 
standardized protocol in a prospective multicenter study. 
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Table 1: Demographic and disease specific characteristics of patients with EGE (n=22) 
Variable  n % 
Gender: male/female 8/14 37/63 
Median age at onset of symptoms (range) 31 (6-74) 
Median age at diagnosis (range) 41.5 (13-78) 




Median duration of disease in years (range)  
8.5 (1-26 
years) 
Positive family history for EGIDS* 2 9 
Clinical history of allergies 9 41 
Atopic Diathesis 6 38 
Allergic Rhinoconjunctivitis 3 14 
Asthma 6 28 
Atopic dermatitis 1 5 
Urticaria 1 5 
Oral allergy syndrome 1 5 
Celiac Disease 1 5 
Clinical and laboratory characteristics 
Symptoms (may be more than one category per patient) n (%) 
Abdominal pain 22 100 
Upper abdominal pain 10 45 
Lower and mid abdominal pain 12 55 
Diarrhea 13 59 
Nausea/Vomiting 8 36 
Reflux 3 14 
Dysphagia 3 14 
Bloating 6 27 
Loss of appetite/Weight loss 4 18 




Fatigue 4 18 
Fever 1 5 
Gastrointestinal bleeding 1 5 
Constipation 1 5 
Laboratory parameters 
Blood eosinophilia (normal range: < 350 Eos/mm3) 13 59 
Elevated total serum immunoglobulin E (normal range: <100 IU/ml)a 8 62 
Elevated C- reactive protein (normal range: <10 mg/ml)b 3 25 
Elevated Fecal calprotectin (normal range: <50 μg/g stool)c 4 66 
Elevated Eosinophil Cationic Protein (normal range: <18 μg/l)d 8 89 
Anemia 4 18 
* EGIDS = Eosinophilic Gastrointestinal Diseases 
a analysis was available for 13 patients; b for 12 patients, c for 6 patients and d for 9 patients 
  




Table 2: Involved intestinal segments and organs at baseline examination 
 
Organ tract involved at baseline examination (may be more than one category per 
patient)  
 n (%) 
 Esophagus   9 41 
 Stomach 3 14 
 Duodenum 7 32 
 Terminal ileum 5 23 
 Large intestine (Colon) 15 68 
 Peritoneum 2 9 
 Pancreas 3 14 
 Eosinophilic Hepatitis and eosinophilic acalculous Cholezystitis 1 5 
 More than one gastrointestinal segment and/or organ involved  17 77 
 
  




Table 3: Drug treatment of patients with Eosinophilic Gastroenteritis 
Treatment used during course of disease (may be more than one category per patient)  
Medication n (%) 
Corticosteroids  21 95 
   Topical esophageal steroids (swallowed fluticasone or budesonide) 8 36 
   Enteral release steroids (budesonide)   10 45 
   Systemic steroids 13 59 
Proton Pump Inhibitor 9 41 
Antihistamines 3 14 
Mast cell stabilizer 2 9 
Azathioprine/6-Mercaptopurine (6-MP)a 5 23 
Methotrexate 1 5 
Antibiotics (ciprofloxacine, metronidazole)b 7 32 
TNFα Blocker (Infliximab, Adalimumab, Certolizumab)c 3 14 
Integrin Antagonist (Vedolizumab) 4 18 
a two patients with side effects of hepatopathy on treatment with azathioprine 
b all patients received combination of ciprofloxacine and metronidazole 
c one patiens received Ada, one patient received Ifx and Ada and one patient received Ada, 
Ifx and Cer 
  





Figure 1:  
Flowchart of screened patients currently enrolled in the SEED. 
 
Figure 2: 
Disease course in patients affected with the mucosal type of EGE (n=20). Correlation 
between disease course of EGE and (A) anatomical distribution upper  (up) vs lower (lo) vs 
upper and lower (up/lo) gastrointestinal tract and (B) number of involved gastrointestinal 
segments. 
 
Figure 3:  
(A) Endoscopic picture the duodenal bulb of a 24 year old male patient with eosinophilic 
duodenitis showing a deep ulceration, inflammation and severe stricture. Follow up 
endoscopy (B) after one year on continuous treatment with vedolizumab showing discrete 
inflammation, superficial erosions and moderate stricture. (C) Endoscopic picture of the 
colon of a 56 year old female patient with eosinophilic colitis showing a mainly unremarkable 
appearing mucosa with areas of edema and low vascular pattern with a (D) representative 
histologic picture of the colon mucosa with eosinophilic colitis showing a dense infiltration 
with eosinophils. (HE staining; original magnification 320x). (E) Endoscopic picture of a 27 
year old female patient with eosinophilic gastroenteritis with involvement of the esophagus 
showing edema, white exudates, furrows and subtle trachealization and (F) of the terminal 
ileum showing an intact mucosa with small, prominent nodules. 
  




Figure 4:  
Patient- and physician-reported outcomes at baseline and at follow up of 4 patients treated 
with the integrin blocker vedolizumab.  
 PGA = patient global assessment; endoscopic activity in the esophagus based on EREF-
scoring; histologic activity with peak eosinophil count; peripheral blood eosinophilia 
(eosinophils/mm3); serum eosinophil cationic protein (ECP) 
  
